Loading...
Header Logo
Keywords
Last Name
Institution

JOSE ANTONIO KARAM

TitleAssociate Professor
InstitutionMD Anderson
DepartmentUrology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Alhalabi O, Karam JA, Tannir NM. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. Curr Opin Urol. 2019 Sep; 29(5):521-525. PMID: 31305271.
      View in: PubMed
    2. Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281. PMID: 31059667.
      View in: PubMed
    3. Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2019 Jul 01. PMID: 31272939.
      View in: PubMed
    4. Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer. 2019 Jun 26. PMID: 31241762.
      View in: PubMed
    5. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 Jun 23. PMID: 31231128.
      View in: PubMed
    6. Larcher A, Wallis CJD, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? Eur Urol Oncol. 2019 Jul; 2(4):365-378. PMID: 31109902.
      View in: PubMed
    7. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 Jun 20; 37(18):1558-1565. PMID: 31067138.
      View in: PubMed
    8. Silagy AW, Sanchez A, Manley BJ, Bensalah K, Bex A, Karam JA, Ljungberg B, Shuch B, Hakimi AA. Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. Eur Urol Focus. 2019 Apr 27. PMID: 31040082.
      View in: PubMed
    9. Wang F, Zhang S, Kim TB, Lin YY, Iqbal R, Wang Z, Mohanty V, Sircar K, Karam JA, Wendl MC, Meric-Bernstam F, Weinstein JN, Ding L, Mills GB, Chen K. Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. Nat Methods. 2019 05; 16(5):401-404. PMID: 30988467.
      View in: PubMed
    10. Li R, Duplisea JJ, Petros FG, González GMN, Tu SM, Karam JA, Huynh TT, Ward JF. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. Eur Urol Oncol. 2019 Mar 29. PMID: 31412007.
      View in: PubMed
    11. Zacharias NM, Ornelas A, Lee J, Hu J, Davis JS, Uddin N, Pudakalakatti S, Menter DG, Karam JA, Wood CG, Hawk ET, Kopetz S, Vilar E, Bhattacharya PK, Millward SW. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. 2019 Mar 22; 58(13):4179-4183. PMID: 30680862.
      View in: PubMed
    12. Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019 Feb 13. PMID: 30759271.
      View in: PubMed
    13. Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 Feb 11; 35(2):204-220.e9. PMID: 30753823.
      View in: PubMed
    14. Patel HD, Karam JA, Allaf ME. Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. J Clin Oncol. 2018 Oct 29; JCO2018790246. PMID: 30372387.
      View in: PubMed
    15. Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol. 2019 01; 75(1):111-128. PMID: 30467042.
      View in: PubMed
    16. Al-Houraibi RK, Aalirezaie A, Adib F, Anoushiravani A, Bhashyam A, Binlaksar R, Blevins K, Bonanzinga T, Chih-Kuo F, Cordova M, Deirmengian GK, Fillingham Y, Frenkel T, Gomez J, Gundtoft P, Harris MA, Harris M, Heller S, Jennings JA, Jiménez-Garrido C, Karam JA, Khlopas A, Klement MR, Komnos G, Krebs V, Lachiewicz P, Miller AO, Mont MA, Montañez E, Romero CA, Schwarzkopf R, Shaffer A, Sharkey PF, Smith BM, Sodhi N, Thienpont E, Villanueva AO, Yazdi H. General Assembly, Prevention, Wound Management: Proceedings of International Consensus on Orthopedic Infections. J Arthroplasty. 2019 02; 34(2S):S157-S168. PMID: 30360978.
      View in: PubMed
    17. Aalirezaie A, Akkaya M, Barnes CL, Bengoa F, Bozkurt M, Cichos KH, Ghanem E, Darouiche RO, Dzerins A, Gursoy S, Illiger S, Karam JA, Klaber I, Komnos G, Lohmann C, Merida E, Mitt P, Nelson C, Paner N, Perez-Atanasio JM, Reed M, Sangster M, Schweitzer D, Simsek ME, Smith BM, Stocks G, Studers P, Talevski D, Teuber J, Travers C, Vince K, Wolf M, Yamada K, Vince K. General Assembly, Prevention, Operating Room Environment: Proceedings of International Consensus on Orthopedic Infections. J Arthroplasty. 2019 02; 34(2S):S105-S115. PMID: 30348570.
      View in: PubMed
    18. Sekino Y, Sakamoto N, Goto K, Honma R, Shigematsu Y, Quoc TP, Sentani K, Oue N, Teishima J, Kawakami F, Karam JA, Sircar K, Matsubara A, Yasui W. Uc.416?+?A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma. BMC Cancer. 2018 Oct 04; 18(1):952. PMID: 30286729.
      View in: PubMed
    19. Yu KJ, Keskin SK, Meissner MA, Petros FG, Wang X, Borregales LD, Gu C, Tamboli P, Matin SF, Wood CG, Karam JA. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer. 2018 10 15; 124(20):4023-4031. PMID: 30276798.
      View in: PubMed
    20. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019 02; 17(1):1-6. PMID: 30287223.
      View in: PubMed
    21. Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2018 Sep 08. PMID: 30206003.
      View in: PubMed
    22. Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN, Wu X. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496. PMID: 30201497.
      View in: PubMed
    23. Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, Wood CG, Matin SF. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2019 Mar; 123(3):447-455. PMID: 30007044.
      View in: PubMed
    24. Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World J Urol. 2018 Dec; 36(12):1973-1980. PMID: 30069581.
      View in: PubMed
    25. Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg. 2018 07; 268(1):172-178. PMID: 28257320.
      View in: PubMed
    26. Sun M, Meyer CP, Karam JA, de Velasco G, Chang SL, Pal SK, Trinh QD, Choueiri TK. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. Eur J Surg Oncol. 2018 09; 44(9):1439-1445. PMID: 29935840.
      View in: PubMed
    27. Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757. PMID: 29635281.
      View in: PubMed
    28. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034. PMID: 29804202.
      View in: PubMed
    29. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol. 2018 Jul; 36(7):343.e1-343.e8. PMID: 29748098.
      View in: PubMed
    30. Meissner MA, McCormick BZ, Karam JA, Wood CG. Adjuvant therapy for advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2018 07; 18(7):663-671. PMID: 29707987.
      View in: PubMed
    31. Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology. 2018 Jun; 116:114-119. PMID: 29578041.
      View in: PubMed
    32. Karam JA. Editorial Comment. J Urol. 2018 06; 199(6):1432. PMID: 29555540.
      View in: PubMed
    33. Bhindi B, Wallis CJD, Boorjian SA, Thompson RH, Farrell A, Kim SP, Karam JA, Capitanio U, Golijanin D, Leibovich BC, Gershman B. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int. 2018 05; 121(5):684-698. PMID: 29319926.
      View in: PubMed
    34. Petros FG, Metcalfe MJ, Yu KJ, Keskin SK, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World J Urol. 2018 Jul; 36(7):1093-1101. PMID: 29488096.
      View in: PubMed
    35. Hutchinson R, Rew C, Chen G, Woldu S, Krabbe LM, Meissner M, Sheth K, Singla N, Shakir N, Master VA, Karam JA, Matin SF, Borregales LD, Wood C, Masterson T, Thompson RH, Boorjian SA, Leibovich BC, Abel EJ, Bagrodia A, Margulis V. The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology. 2018 May; 115:119-124. PMID: 29499258.
      View in: PubMed
    36. McCormick B, Meissner MA, Karam JA, Wood CG. Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2017 Nov 27; 1(2):115-121. PMID: 30334013.
      View in: PubMed
    37. Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer. 2018 04; 16(2):e443-e450. PMID: 29113770.
      View in: PubMed
    38. Han G, Zhao W, Song X, Kwok-Shing Ng P, Karam JA, Jonasch E, Mills GB, Zhao Z, Ding Z, Jia P. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. BMC Genomics. 2017 Oct 03; 18(Suppl 6):678. PMID: 28984208.
      View in: PubMed
    39. Karam JA, Wood CG. Editorial Comment. J Urol. 2018 01; 199(1):52. PMID: 28945990.
      View in: PubMed
    40. Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, Matin SF, Wood CG, Karam JA. Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. J Urol. 2018 02; 199(2):393-400. PMID: 28941919.
      View in: PubMed
    41. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831. PMID: 28832979.
      View in: PubMed
    42. Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953. PMID: 28731777.
      View in: PubMed
    43. Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696. PMID: 28710314.
      View in: PubMed
    44. Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. J Urol. 2017 12; 198(6):1269-1277. PMID: 28709887.
      View in: PubMed
    45. Chéry L, Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA. The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology. 2017 10; 108:114-121. PMID: 28705573.
      View in: PubMed
    46. D'Andrea D, Moschini M, Foerster B, Abufaraj M, Margulis V, Karam J, Lotan Y, Raman J, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Haitel A, Shariat SF. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. Eur Urol Focus. 2019 01; 5(1):97-103. PMID: 28753840.
      View in: PubMed
    47. Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2017 12; 198(6):1253-1262. PMID: 28668287.
      View in: PubMed
    48. Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol. 2018 01; 73(1):71-78. PMID: 28592388.
      View in: PubMed
    49. Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627. PMID: 28543182.
      View in: PubMed
    50. Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, Lorentz CA, Bloom E, Bauman TM, Wood CG, Blute ML. Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol. 2017 10; 198(4):810-816. PMID: 28411071.
      View in: PubMed
    51. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537. PMID: 28411072.
      View in: PubMed
    52. Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, Choueiri TK. Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. Eur Urol. 2017 08; 72(2):171-174. PMID: 28359734.
      View in: PubMed
    53. Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 08; 198(2):281-288. PMID: 28268170.
      View in: PubMed
    54. Meissner MA, Karam JA. Nephrometry scoring systems: valuable research tools, but can they be applied in daily clinical practice? BJU Int. 2017 03; 119(3):364-365. PMID: 28211238.
      View in: PubMed
    55. Karam JA, Parikh RY, Nayak D, Rosenkranz D, Gangaraju VK. Co-chaperone Hsp70/Hsp90-organizing protein (Hop) is required for transposon silencing and Piwi-interacting RNA (piRNA) biogenesis. J Biol Chem. 2017 04 14; 292(15):6039-6046. PMID: 28193840.
      View in: PubMed
    56. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370. PMID: 28216278.
      View in: PubMed
    57. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143.
      View in: PubMed
    58. Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792. PMID: 27860149.
      View in: PubMed
    59. Pal SK, Karam JA, Bergerot P, Agarwal N. Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma. J Clin Oncol. 2016 11 10; 34(32):3825-3826. PMID: 27601540.
      View in: PubMed
    60. Abufaraj M, Moschini M, Soria F, Gust K, Özsoy M, Mathieu R, Rouprêt M, Margulis V, Karam JA, Wood CG, Briganti A, Bensalah K, Haitel A, Shariat SF. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017 Jul; 35(7):1073-1080. PMID: 27830374.
      View in: PubMed
    61. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682. PMID: 27789196.
      View in: PubMed
    62. Kawakami F, Rao P, Tamboli P, Wood CG, Karam JA. Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial. J Urol. 2017 03; 197(3 Pt 1):559-565. PMID: 27678298.
      View in: PubMed
    63. Pal SK, Karam JA, Chennamsetty A, Jones JO. Biomarkers in Genitourinary Cancers: Blazing the Path Forward. Eur Urol. 2017 02; 71(2):247-248. PMID: 27639532.
      View in: PubMed
    64. Chery LJ, Karam JA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2016 Sep; 14(9):696-703. PMID: 27673288.
      View in: PubMed
    65. Biebighauser KC, Gao J, Rao P, Landon G, Pagliaro L, Dinney CPN, Karam J, Navai N. Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. Asian J Urol. 2017 Apr; 4(2):124-127. PMID: 29264217.
      View in: PubMed
    66. Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Özsoy M, Remzi M, Gust KM, Shariat SF. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World J Urol. 2017 Feb; 35(2):251-259. PMID: 27272502.
      View in: PubMed
    67. Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016 Dec 15; 22(24):6236-6246. PMID: 27256309.
      View in: PubMed
    68. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, Briganti A, Xylinas E, Shariat SF. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol. 2017 Jan; 35(1):121-130. PMID: 27209168.
      View in: PubMed
    69. Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology. 2016 Aug; 94:314.e1-7. PMID: 27215483.
      View in: PubMed
    70. Favaretto RL, Bahadori A, Mathieu R, Haitel A, Grubmüller B, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Cunha IW, Zequi SC, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, Lotan Y, Bachmann A, Rink M, Briganti A, Shariat SF. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017 Jan; 35(1):113-120. PMID: 27129576.
      View in: PubMed
    71. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84. PMID: 27036304.
      View in: PubMed
    72. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785.
      View in: PubMed
    73. Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57. PMID: 26895810.
      View in: PubMed
    74. Thomas AZ, Blute ML, Seitz C, Habra MA, Karam JA. Management of the Incidental Adrenal Mass. Eur Urol Focus. 2016 Feb; 1(3):223-230. PMID: 28723391.
      View in: PubMed
    75. Huang H, Tamboli P, Karam JA, Vikram R, Zhang M. Secondary malignancies diagnosed using kidney needle core biopsies: a clinical and pathological study of 75 cases. Hum Pathol. 2016 06; 52:55-60. PMID: 26980018.
      View in: PubMed
    76. Matin SF, Melquist J, Karam JA. Author reply. Urology. 2016 Jan; 87:222-3. PMID: 27243090.
      View in: PubMed
    77. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26. PMID: 26707613.
      View in: PubMed
    78. Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82. PMID: 26655847.
      View in: PubMed
    79. Mbeutcha A, Lucca I, Margulis V, Karam JA, Wood CG, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Rieken M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Seitz C, Remzi M, Shariat SF, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World J Urol. 2016 Aug; 34(8):1155-61. PMID: 26658888.
      View in: PubMed
    80. Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers Z, Frampton G, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. Eur Urol Focus. 2016 Jun; 2(2):204-209. PMID: 28723536.
      View in: PubMed
    81. Pal SK, Choueiri TK, Karam JA, Heng DY. Metastatic renal cell carcinoma: Contending with a sea change in therapy. Urol Oncol. 2015 Dec; 33(12):507-8. PMID: 26584741.
      View in: PubMed
    82. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74. PMID: 26626617.
      View in: PubMed
    83. Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016 Apr; 8(2):130-41. PMID: 27034725.
      View in: PubMed
    84. Lotan Y, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, Margulis V. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urol Oncol. 2016 Apr; 34(4):167.e9-16. PMID: 26602092.
      View in: PubMed
    85. Karam JA, Matin SF. Positive Margins after Radical Nephrectomy with Venous Thrombectomy: Controversies and Treatment Options. J Urol. 2016 Feb; 195(2):241-2. PMID: 26585683.
      View in: PubMed
    86. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15. PMID: 26551148.
      View in: PubMed
    87. Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol. 2015 Dec; 33(12):528-37. PMID: 26546481.
      View in: PubMed
    88. Melquist JJ, Redrow G, Delacroix S, Park A, Faria EE, Karam JA, Matin SF. Comparison of Single-docking Robotic-assisted and Traditional Laparoscopy for Retroperitoneal Lymph Node Dissection During Nephroureterectomy With Bladder Cuff Excision for Upper-tract Urothelial Carcinoma. Urology. 2016 Jan; 87:216-23. PMID: 26494291.
      View in: PubMed
    89. Abel EJ, Margulis V, Bauman TM, Karam JA, Christensen WP, Krabbe LM, Haddad A, Golla V, Wood CG. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU Int. 2016 Jun; 117(6B):E87-94. PMID: 26305276.
      View in: PubMed
    90. Adibi M, Kenney PA, Thomas AZ, Borregales LD, Nogueras-González GM, Wang X, Devine CE, Karam JA, Wood CG. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. Eur Urol. 2016 Feb; 69(2):352-60. PMID: 26382085.
      View in: PubMed
    91. Thomas AZ, Adibi M, Borregales LD, Wood CG, Karam JA. Role of metastasectomy in metastatic renal cell carcinoma. Curr Opin Urol. 2015 Sep; 25(5):381-9. PMID: 26125508.
      View in: PubMed
    92. Lee BM, Singh Ghotra V, Karam JA, Hernandez M, Pratt G, Cata JP. Regional anesthesia/analgesia and the risk of cancer recurrence and mortality after prostatectomy: a meta-analysis. Pain Manag. 2015 Sep; 5(5):387-95. PMID: 26250850.
      View in: PubMed
    93. Bex A, Powles T, Karam JA. Role of targeted therapy in combination with surgery in renal cell carcinoma. Int J Urol. 2016 Jan; 23(1):5-12. PMID: 26238981.
      View in: PubMed
    94. Mathieu R, Klatte T, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Rink M, Kluth LA, Scherr DS, Robinson BD, Shariat SF. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2015 Nov; 33(11):495.e15-22. PMID: 26228160.
      View in: PubMed
    95. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24. PMID: 27499906.
      View in: PubMed
    96. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5. PMID: 26032863.
      View in: PubMed
    97. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, Wood CG, Karam JA. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int. 2016 May; 117(5):775-82. PMID: 26053895.
      View in: PubMed
    98. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275.
      View in: PubMed
    99. Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, Palma NA, Stein MN, Johnson A, Squillace R, Elvin JA, Chmielecki J, Yelensky R, Yakirevich E, Lipson D, Lin DI, Miller VA, Stephens PJ, Ali SM, Ross JS. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. Eur Urol. 2016 09; 70(3):516-21. PMID: 26149668.
      View in: PubMed
    100. Karam JA, Devine CE, Fellman BM, Urbauer DL, Abel EJ, Allaf ME, Bex A, Lane BR, Thompson RH, Wood CG. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial. BJU Int. 2016 Apr; 117(4):629-35. PMID: 26033220.
      View in: PubMed
    101. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35. PMID: 26111976.
      View in: PubMed
    102. Thomas AZ, Adibi M, Borregales LD, Karam JA, Wood CG. Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol. 2015 Jun; 4(3):301-9. PMID: 26815334.
      View in: PubMed
    103. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29. PMID: 26014097.
      View in: PubMed
    104. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23. PMID: 26004164.
      View in: PubMed
    105. Gayed BA, Gillen J, Christie A, Peña-Llopis S, Xie XJ, Yan J, Karam JA, Raj G, Sagalowsky AI, Lotan Y, Margulis V, Brugarolas J. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. BMC Urol. 2015 Apr 03; 15:24. PMID: 25885592.
      View in: PubMed
    106. Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, Karam JA. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015 Jul; 116(1):85-92. PMID: 25395040.
      View in: PubMed
    107. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22. PMID: 25758610.
      View in: PubMed
    108. Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep. 2015 Mar 01; 3(2):18-20. PMID: 26120560.
      View in: PubMed
    109. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9. PMID: 25700975.
      View in: PubMed
    110. Karam JA, Babaian KN, Tannir NM, Matin SF, Wood CG. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol. 2015 Jun; 67(2):149-56. PMID: 25645343.
      View in: PubMed
    111. Karam JA, Wood CG, Compton ZR, Rao P, Vikram R, Ahrar K, Matin SF. Salvage surgery after energy ablation for renal masses. BJU Int. 2015 Jan; 115(1):74-80. PMID: 24656119.
      View in: PubMed
    112. Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol. 2014 Dec 22; 14:138. PMID: 25532962.
      View in: PubMed
    113. Karam JA, Huang RC, Abraham JA, Parvizi J. Total joint arthroplasty in cancer patients. J Arthroplasty. 2015 May; 30(5):758-61. PMID: 25583683.
      View in: PubMed
    114. Karam J, Tsiouris A, Vazquez J, Shepard A. Cryptococcal aortitis presenting as a symptomatic abdominal aortic aneurysm. Ann Vasc Surg. 2015 Feb; 29(2):363.e9-363.e11. PMID: 25452084.
      View in: PubMed
    115. Koh MY, Nguyen V, Lemos R, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer Res. 2015 Jan 15; 75(2):316-29. PMID: 25421578.
      View in: PubMed
    116. Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. J Urol. 2015 May; 193(5):1486-93. PMID: 25451830.
      View in: PubMed
    117. Adibi M, Karam JA, Wood CG. Reporting geographic and temporal trends in renal cell carcinoma: why is this important? Eur Urol. 2015 Mar; 67(3):531-2. PMID: 25454608.
      View in: PubMed
    118. Babaian KN, Kim DY, Kenney PA, Wood CG, Wong J, Sanchez C, Fang JE, Gerber JA, Didic A, Wahab A, Golla V, Torres C, Tamboli P, Qiao W, Matin SF, Wood CG, Karam JA. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol. 2015 Apr; 193(4):1101-7. PMID: 25390078.
      View in: PubMed
    119. Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclerq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. Urology. 2014 Nov; 84(5):1134-40. PMID: 25443916.
      View in: PubMed
    120. Pal SK, He M, Tong T, Wu H, Liu X, Lau C, Wang JH, Warden C, Wu X, Signoretti S, Choueiri TK, Karam JA, Jones JO. RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res. 2015 Jan; 13(1):130-7. PMID: 25183163.
      View in: PubMed
    121. Karmali RJ, Suami H, Wood CG, Karam JA. Lymphatic drainage in renal cell carcinoma: back to the basics. BJU Int. 2014 Dec; 114(6):806-17. PMID: 24841690.
      View in: PubMed
    122. Kim DY, Karam JA. For the RECORD, we should SWITCH our treatment AXIS before the SUNRISES and TARGET the BEST treatments before INTORSECTing with a GOLD METEOR: a tale of sequences and combinations. Eur Urol. 2015 Jan; 67(1):111-113. PMID: 24953406.
      View in: PubMed
    123. Kim DY, Karam JA. Editorial Comment to Growing teratoma syndrome: clinical and radiographic characteristics. Int J Urol. 2014 Sep; 21(9):909. PMID: 24796961.
      View in: PubMed
    124. Karam JA, Zmistowski B, Restrepo C, Hozack WJ, Parvizi J. Fewer postoperative fevers: an unexpected benefit of multimodal pain management? Clin Orthop Relat Res. 2014 May; 472(5):1489-95. PMID: 24615425.
      View in: PubMed
    125. Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol. 2014 Jun; 32(3):631-42. PMID: 24744223.
      View in: PubMed
    126. Culp SH, Karam JA, Wood CG. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol. 2014 Jul; 32(5):561-8. PMID: 24709415.
      View in: PubMed
    127. Abel EJ, Carrasco A, Karam J, Tamboli P, Delacroix S, Vaporciyan AA, Wood CG. Positive vascular wall margins have minimal impact on cancer outcomes in patients with non-metastatic renal cell carcinoma (RCC) with tumour thrombus. BJU Int. 2014 Nov; 114(5):667-73. PMID: 24128265.
      View in: PubMed
    128. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42. PMID: 24518767.
      View in: PubMed
    129. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014 Nov; 66(5):874-80. PMID: 24560330.
      View in: PubMed
    130. Tokarski AT, Karam JA, Zmistowski B, Deirmengian CA, Deirmengian GK. Clostridium difficile is common in patients with postoperative diarrhea after hip and knee arthroplasty. J Arthroplasty. 2014 Jun; 29(6):1110-3. PMID: 24530206.
      View in: PubMed
    131. Kim DY, Wood CG, Karam JA. Treating the two extremes in renal cell carcinoma: management of small renal masses and cytoreductive nephrectomy in metastatic disease. Am Soc Clin Oncol Educ Book. 2014; e214-21. PMID: 24857105.
      View in: PubMed
    132. Alijanipour P, Karam J, Llinás A, Vince KG, Zalavras C, Austin M, Garrigues G, Heller S, Huddleston J, Klatt B, Krebs V, Lohmann C, McPherson EJ, Molloy R, Oliashirazi A, Schwaber M, Sheehan E, Smith E, Sterling R, Stocks G, Vaidya S. Operative environment. J Orthop Res. 2014 Jan; 32 Suppl 1:S60-80. PMID: 24464899.
      View in: PubMed
    133. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, Shariat SF, Robinson BD, Margulis V. Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol. 2014 Aug; 66(2):379-85. PMID: 24388440.
      View in: PubMed
    134. Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J. Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg Am. 2013 Dec 18; 95(24):2177-84. PMID: 24352771.
      View in: PubMed
    135. Alijanipour P, Karam J, Llinás A, Vince KG, Zalavras C, Austin M, Garrigues G, Heller S, Huddleston J, Klatt B, Krebs V, Lohmann C, McPherson EJ, Molloy R, Oliashirazi A, Schwaber M, Sheehan E, Smith E, Sterling R, Stocks G, Vaidya S. Operative environment. J Arthroplasty. 2014 Feb; 29(2 Suppl):49-64. PMID: 24342274.
      View in: PubMed
    136. Cai J, Karam JA, Parvizi J, Smith EB, Sharkey PF. Aquacel surgical dressing reduces the rate of acute PJI following total joint arthroplasty: a case-control study. J Arthroplasty. 2014 Jun; 29(6):1098-100. PMID: 24405622.
      View in: PubMed
    137. Ngo TC, Wood CG, Karam JA. Biomarkers of renal cell carcinoma. Urol Oncol. 2014 Apr; 32(3):243-51. PMID: 24239464.
      View in: PubMed
    138. Morgan JA, Tsiouris A, Nemeh HW, Hodari A, Karam J, Brewer RJ, Paone G. Impact of concomitant cardiac procedures performed during implantation of long-term left ventricular assist devices. J Heart Lung Transplant. 2013 Dec; 32(12):1255-61. PMID: 24135274.
      View in: PubMed
    139. Karam JA, Bloomfield MR, DiIorio TM, Irizarry AM, Sharkey PF. Evaluation of the efficacy and safety of tranexamic acid for reducing blood loss in bilateral total knee arthroplasty. J Arthroplasty. 2014 Mar; 29(3):501-3. PMID: 24051240.
      View in: PubMed
    140. Laguna MP. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710. PMID: 24120769.
      View in: PubMed
    141. Karam J, Shepard A, Rubinfeld I. Predictors of operative mortality following major lower extremity amputations using the National Surgical Quality Improvement Program public use data. J Vasc Surg. 2013 Nov; 58(5):1276-82. PMID: 23830311.
      View in: PubMed
    142. Faria EF, Caputo PA, Wood CG, Karam JA, Nogueras-González GM, Matin SF. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol. 2014 Feb; 32(1):265-71. PMID: 23783881.
      View in: PubMed
    143. Karam J, Tsiouris A, Shepard A, Velanovich V, Rubinfeld I. Simplified frailty index to predict adverse outcomes and mortality in vascular surgery patients. Ann Vasc Surg. 2013 Oct; 27(7):904-8. PMID: 23711971.
      View in: PubMed
    144. Karam JA, Wood CG. Words of wisdom: re: prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Eur Urol. 2013 Apr; 63(4):769. PMID: 23438394.
      View in: PubMed
    145. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005. PMID: 23510233.
      View in: PubMed
    146. Tsiouris A, Borgi J, Karam J, Nemeh HW, Paone G, Brewer RJ, Morgan JA. Ischemic versus nonischemic dilated cardiomyopathy: the implications of heart failure etiology on left ventricular assist device outcomes. ASAIO J. 2013 Mar-Apr; 59(2):130-5. PMID: 23438774.
      View in: PubMed
    147. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7. PMID: 23419322.
      View in: PubMed
    148. Karam JA, Tokarski AT, Ciccotti M, Austin MS, Deirmengian GK. Revision total hip arthroplasty in younger patients: indications, reasons for failure, and survivorship. Phys Sportsmed. 2012 Nov; 40(4):96-101. PMID: 23306419.
      View in: PubMed
    149. Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM. Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol. 2013 Feb; 63(2):244-51. PMID: 23063455.
      View in: PubMed
    150. Kenney PA, Karam JA. Percutaneous cryoablation of solitary sporadic renal cell carcinomas. BJU Int. 2012 Dec; 110(11 Pt B):E532. PMID: 22583351.
      View in: PubMed
    151. Karam JA, Wood CG. The effects of temporary ischemia in partial nephrectomy on renal functional outcomes: how can effects best be estimated, and can they be mitigated? Eur Urol. 2012 Jul; 62(1):136-8; discussion 138-9. PMID: 22410575.
      View in: PubMed
    152. Kenney PA, Karam JA. Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. BJU Int. 2012 Sep; 110(6 Pt B):E191. PMID: 22321381.
      View in: PubMed
    153. Karam JA, Wood CG. Management of small renal masses: watch, cut, freeze, or fry? Eur Urol. 2012 May; 61(5):905-6; discussion 906-7. PMID: 22310973.
      View in: PubMed
    154. Tsiouris A, Karam J, Shepard AD. Incidental diagnosis of idiopathic gonadal vein thrombosis. Vasa. 2012 Jan; 41(1):67-9. PMID: 22247063.
      View in: PubMed
    155. Kenney PA, Karam JA. Editorial comment. J Urol. 2012 Feb; 187(2):492. PMID: 22177914.
      View in: PubMed
    156. Karam JA, Wood CG. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am. 2011 Aug; 25(4):753-64. PMID: 21763966.
      View in: PubMed
    157. Abel EJ, Karam JA, Carrasco A, Matin SF. Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J Endourol. 2011 Aug; 25(8):1323-7. PMID: 21774667.
      View in: PubMed
    158. West CA, Karam J, Poopat C, Shepard AD, Nypaver TJ, Weaver M. Late endovascular aneurysm repair infection presenting with juxatrenal aortic rupture treated with in situ aortic replacement. J Vasc Surg. 2011 Oct; 54(4):1157-60. PMID: 21723686.
      View in: PubMed
    159. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011 Oct; 108(7):1119-23. PMID: 21426474.
      View in: PubMed
    160. Karam JA. Editorial comment: Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int. 2011 Aug; 108(4):537-8. PMID: 21371243.
      View in: PubMed
    161. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8. PMID: 21367518.
      View in: PubMed
    162. Karam JA, Wood CG. The dark side of targeted therapy. Eur Urol. 2011 Apr; 59(4):541-2. PMID: 21295398.
      View in: PubMed
    163. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44. PMID: 21167518.
      View in: PubMed
    164. Karam JA, Ahrar K, Matin SF. Ablation of kidney tumors. Surg Oncol Clin N Am. 2011 Apr; 20(2):341-53, viii. PMID: 21377587.
      View in: PubMed
    165. Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol. 2011 Apr; 59(4):619-28. PMID: 21167632.
      View in: PubMed
    166. Karam JA, Huang S, Fan J, Stanfield J, Schultz RA, Pong RC, Sun X, Mason RP, Xie XJ, Niu G, Chen X, Frenkel EP, Sagalowsky AI, Hsieh JT. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder. Int J Cancer. 2011 Jun 15; 128(12):2823-32. PMID: 20734393.
      View in: PubMed
    167. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7. PMID: 20846689.
      View in: PubMed
    168. Karam JA, Kamat AM. Optimal timing of chemotherapy and cystectomy. F1000 Med Rep. 2010 Jun 23; 2. PMID: 20948836.
      View in: PubMed
    169. Karam JA, Wood CG. Editorial comment. J Urol. 2010 Mar; 183(3):870; discussion 870. PMID: 20083268.
      View in: PubMed
    170. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009 Nov 15; 15(22):7012-9. PMID: 19903782.
      View in: PubMed
    171. Karam JA, Raj GV. Growing teratoma syndrome. Urology. 2009 Oct; 74(4):783-4. PMID: 19647298.
      View in: PubMed
    172. Khreiss M, Karam J, Musallam KM, Al Harakeh AB, Nasr VG, Abi Saad GS. Distinctive presentation of a diaphragmatic hernia 15 years after a traumatic insult. Ann Thorac Surg. 2009 Aug; 88(2):651-3. PMID: 19632432.
      View in: PubMed
    173. Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009 Sep; 182(3):907-13. PMID: 19616250.
      View in: PubMed
    174. Decker DB, Karam JA, Wilcox DT. Pediatric hemorrhagic cystitis. J Pediatr Urol. 2009 Aug; 5(4):254-64. PMID: 19303365.
      View in: PubMed
    175. Shariat SF, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol. 2009 Jan; 55(1):250-2. PMID: 20050019.
      View in: PubMed
    176. Karam JA, Shariat SF, Hsieh JT, Knowles MA. Genomics: a preview of genomic medicine. BJU Int. 2008 Nov; 102(9 Pt B):1221-7. PMID: 19035885.
      View in: PubMed
    177. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res. 2008 Jun 15; 14(12):3785-91. PMID: 18559597.
      View in: PubMed
    178. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res. 2008 Jun 01; 14(11):3362-6. PMID: 18519764.
      View in: PubMed
    179. Karam JA, Margulis V, Montorsi F, Karakiewicz PI, Lotan Y, Kikuchi E, Weizer A, Zigeuner R, Bolenz C, Shariat SF. Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy--results from a multicenter study. Eur Urol. 2008 Oct; 54(4):961-3. PMID: 18485573.
      View in: PubMed
    180. Shariat SF, Jenkins A, Roehrborn CG, Karam JA, Stage KH, Karakiewicz PI. Features and outcomes of patients with grade IV renal injury. BJU Int. 2008 Sep; 102(6):728-33; discussion 733. PMID: 18435808.
      View in: PubMed
    181. Shariat SF, Karam JA, Raman JD. Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. Biomark Med. 2008 Apr; 2(2):165-80. PMID: 20477438.
      View in: PubMed
    182. Karam JA, Sagalowsky AI. Minimally invasive radical cystectomy for bladder cancer? Lancet Oncol. 2008 Apr; 9(4):317-8. PMID: 18374289.
      View in: PubMed
    183. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res. 2008 Mar 01; 14(5):1418-22. PMID: 18316564.
      View in: PubMed
    184. Fan J, Stanfield J, Guo Y, Karam JA, Frenkel E, Sun X, Hsieh JT. Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer. Clin Cancer Res. 2008 Feb 15; 14(4):1200-7. PMID: 18281555.
      View in: PubMed
    185. Svatek RS, Karam J, Karakiewicz PI, Gallina A, Casella R, Roehrborn CG, Shariat SF. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J Urol. 2008 Feb; 179(2):478-84; discussion 484. PMID: 18076936.
      View in: PubMed
    186. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008 Jan; 18(1):1-8. PMID: 18090481.
      View in: PubMed
    187. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol. 2008; 10(2):120-35. PMID: 18660854.
      View in: PubMed
    188. Hsieh JT, Karam JA, Min W. Genetic and biologic evidence that implicates a gene in aggressive prostate cancer. J Natl Cancer Inst. 2007 Dec 19; 99(24):1823-4. PMID: 18073373.
      View in: PubMed
    189. Karam JA, Kabbani W, Sagalowsky AI. Pseudosarcomatous fibromyxoid tumor of the bladder. Urol Oncol. 2008 May-Jun; 26(3):291-4. PMID: 18452822.
      View in: PubMed
    190. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(2):112-20. PMID: 17998918.
      View in: PubMed
    191. Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int. 2008 Mar; 101(6):675-83. PMID: 17941930.
      View in: PubMed
    192. Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5377-84. PMID: 17875766.
      View in: PubMed
    193. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007 Sep; 70(3):482-6. PMID: 17905101.
      View in: PubMed
    194. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4400-6. PMID: 17671122.
      View in: PubMed
    195. Shariat SF, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol. 2007 Aug; 3(4):449-61. PMID: 17661720.
      View in: PubMed
    196. Karam JA, Vazquez DV, Lin VK, Zimmern PE. Elastin expression and elastic fibre width in the anterior vaginal wall of postmenopausal women with and without prolapse. BJU Int. 2007 Aug; 100(2):346-50. PMID: 17532852.
      View in: PubMed
    197. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007 May 01; 67(6):614-22. PMID: 17299799.
      View in: PubMed
    198. Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer. 2007 Apr 15; 120(8):1795-802. PMID: 17230511.
      View in: PubMed
    199. Svatek RS, Karam JA, Rogers TE, Shulman MJ, Margulis V, Benaim EA. Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens. Prostate Cancer Prostatic Dis. 2007; 10(3):279-82. PMID: 17325718.
      View in: PubMed
    200. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007 Feb; 8(2):128-36. PMID: 17267327.
      View in: PubMed
    201. Karam JA, Baker LA. Focal orchitis presenting as bilateral testicular masses. J Pediatr Urol. 2007 Aug; 3(4):337-9. PMID: 18947769.
      View in: PubMed
    202. Chen H, Karam JA, Schultz R, Zhang Z, Duncan C, Hsieh JT. Cloning of mouse Dab2ip gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate. DNA Cell Biol. 2006 Apr; 25(4):232-45. PMID: 16629596.
      View in: PubMed
    203. Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol. 2006 Mar-Apr; 24(2):152-60. PMID: 16520279.
      View in: PubMed
    204. Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol. 2006 Apr; 49(4):666-74. PMID: 16423446.
      View in: PubMed
    205. Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol. 2005 Sep; 48(3):424-31. PMID: 15963628.
      View in: PubMed
    206. Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Bex F, de Thé H, Hermine O, Bazarbachi A. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005 Jan 13; 24(3):419-30. PMID: 15543232.
      View in: PubMed
    207. Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V. The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate. 2004 Sep 01; 60(4):310-6. PMID: 15264242.
      View in: PubMed
    208. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology. 2004 Apr; 63(4):732-6. PMID: 15072890.
      View in: PubMed
    209. Karam JA, Baker LA. Images in clinical medicine. True hermaphroditism. N Engl J Med. 2004 Jan 22; 350(4):393. PMID: 14736931.
      View in: PubMed
    210. Karam JA, Shulman MJ, Benaim EA. Impact of training level of urology residents on the detection of prostate cancer on TRUS biopsy. Prostate Cancer Prostatic Dis. 2004; 7(1):38-40. PMID: 14999236.
      View in: PubMed
    211. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Molecular imaging in prostate cancer. J Cell Biochem. 2003 Oct 15; 90(3):473-83. PMID: 14523981.
      View in: PubMed
    212. Boukhman MP, Karam JH, Shaver J, Siperstein AE, Duh QY, Clark OH. Insulinoma--experience from 1950 to 1995. West J Med. 1998 Aug; 169(2):98-104. PMID: 9735690.
      View in: PubMed
    213. Bohannon NV, Karam JH, Lorenzi M, Gerich JE, Matin SB, Forsham PH. Plasma glucagon suppression by phenformin in man. Diabetologia. 1977 Sep; 13(5):503-8. PMID: 908474.
      View in: PubMed
    214. Conlay LA, Karam JH, Matin SB, Loewenstein JE. Serum phenformin concentrations in patients with phenformin-associated lactic acidosis. Diabetes. 1977 Jul; 26(7):628-31. PMID: 406157.
      View in: PubMed
    215. Matin SB, Karam JH, Forshan PH. Simple elcetron capture gas chromatographic method for the determination of oral hypoglycemic biguanidis in biological fluids. Anal Chem. 1975 Mar; 47(3):545-8. PMID: 1137127.
      View in: PubMed
    216. Karam JH, Matin SB, Forsham PH. Antidiabetic drugs after the University Group Diabetes Program (UGDP). Annu Rev Pharmacol. 1975; 15:351-66. PMID: 1096790.
      View in: PubMed
    217. Matin SB, Wan SH, Karam JH. Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther. 1974 Dec; 16(6):1052-8. PMID: 4433472.
      View in: PubMed
    218. Matin SB, Karam JH, Forsham PH, Knight JB. Determination of phenformin in biological fluids using chemical ionization mass spectrometry. Biomed Mass Spectrom. 1974 Oct; 1(5):320-2. PMID: 4464999.
      View in: PubMed
    219. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology. 1-7.
    220. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:166.e21-166.e29.
    221. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. European Urology.
    222. True Hermaphroditism. New England Journal of Medicine. 350:393.
    223. Intratumoral heterogeneity. Cancer.
    224. Management and outcomes of patients with renal medullary carcinoma. BJU International.
    225. Bladder cancer screening and future directions in urine-based markers for bladder urothelial carcinoma. Laboratory Medicine. 38:116-120.
    226. Genomic DNA hypomethylation and risk of renal cell carcinoma. Clinical Cancer Research. 22:2074-2082.
    227. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urologic Oncology: Seminars and Original Investigations. 34:167.e9-167.e16.
    228. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clinical Advances in Hematology and Oncology. 14:696-703.
    229. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney. BJU International.
    230. Biomarkers in Genitourinary Cancers. European Urology. 71:247-248.
    231. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC). BJU International. 117:629-635.
    232. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma Urological oncology. BMC Urology. 15:1-8.
    233. Anti-cancer strategy of transitional cell carcinoma of bladder based on induction of different types of programmed cell deaths. 25-50.
    234. Management of non-clear cell renal cell carcinoma. 373-385.
    235. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:427.e17-427.e23.
    236. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN). European Urology.
    237. Cytoreductive surgery in the era of targeted molecular therapy. Translational Andrology and Urology. 4:301-309.
    238. Management of the Incidental Adrenal Mass. European Urology Focus. 1:223-230.
    239. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. European Urology Focus. 2:204-209.
    240. Epigenetics in prostate cancer. 213-242.
    241. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International.
    242. Benign prostatic hyperplasia. Journal of Urology. 173:1266-1267.
    243. DNA methylation signature reveals cell ontogeny of renal cell carcinomas. Clinical Cancer Research. 22:6236-6246.
    244. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. European Urology. 66:874-880.
    245. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. 33:495.e15-495.e22.
    246. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology. 94:314.e1-314.e7.
    247. Developing a clear path forward for non-clear-cell renal carcinoma. Journal of Clinical Oncology. 34:3825-3826.
    248. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. European Urology.
    249. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    250. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. World Journal of Urology. 1-7.
    251. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Therapeutic Advances in Urology. 8:130-141.
    252. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology.
    253. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    254. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma. World Journal of Urology. 1-8.
    255. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma. Modern Pathology. 28:1225-1235.
    256. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology. 1-9.
    257. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology. 1-10.
    258. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib. Urology Case Reports. 3:18-20.
    259. Postoperative surveillance protocols for renal cell carcinoma. 283-305.
    260. Metastases to the kidney. BJU International.
    261. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation. Journal of Urology.
    262. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. British Journal of Cancer. 116:77-84.
    263. Urine cytology and commercially available urine-based markers for monitoring of bladder urothelial carcinoma. Laboratory Medicine. 38:48-52.
    264. Secondary malignancies diagnosed using kidney needle core biopsies. Human Pathology. 52:55-60.
    265. Role of targeted therapy in combination with surgery in renal cell carcinoma. International Journal of Urology. 23:5-12.
    266. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations.
    267. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus. BJU International.
    268. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene.
    269. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma. World Journal of Urology. 1-8.
    270. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European Urology.
    271. Genomic investigation of etiologic heterogeneity. BMC Medical Research Methodology. 14.
    272. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer immunology research. 3:1017-1029.
    KARAM's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description